New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
05:55 EDTKINKindred Biosciences downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded Kindred Biosciences citing valuation following the company's Q4 results but raised its price target for shares to $25 from $20.
News For KIN From The Last 14 Days
Check below for free stories on KIN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:07 EDTKINOn The Fly: Pre-market Movers
Subscribe for More Information
08:20 EDTKINKindred Biosciences price target lowered to $19 from $30 at BMO Capital
BMO Capital cut its price target on Kindred after the company announced that its pivotal study of CereKin for the treatment of osteoarthritis in dogs did not meet its primary endpoint. However, the firm thinks that each of two other trials that the company is undertaking has a 70% chance of succeeding. The firm believes that the company has many more shots on goal, and it keeps an Outperform rating on the shares.
August 20, 2014
18:35 EDTKINOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTKINKindred reports pivotal field study of CereKin did not meet primary endpoint
Subscribe for More Information
16:00 EDTKINKindred Biosciences trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use